Jiangxi Jemincare Group Co. Ltd. and Shanghai Jemincare Pharmaceuticals Co. Ltd. have divulged tricyclic hypoxia inducible factor 2-alpha (HIF-2-alpha; EPAS1) inhibitors reported to be useful for the treatment of cancer, von Hippel-Lindau disease, pulmonary hypertension and inflammatory bowel disease.
Insilico Medicine IP Ltd. has described new TRAF2 and NCK-interacting protein kinase (TNIK) and/or mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4; HGK; MEKKK4) inhibitors reported to be useful for the treatment of cancer and fibrosis.
Medshine Discovery Inc. has patented substituted pyridine-2,4-dione derivatives acting as cardiac myosin inhibitors. As such, they are reported to be useful for the treatment of hypertrophic cardiomyopathy and heart failure.
F. Hoffmann-La Roche Ltd. has discovered benzothiazolyl bicyclo[1.1.1]pentane derivatives acting as hepatitis B virus (HBV) HBeAg and HBsAg secretion inhibitors, reported to be useful for the treatment of HBV infections.
Kashiv Biosciences LLC has synthesized prodrugs of azo compounds reported to be useful for the treatment of interstitial cystitis and pain, among other disorders.
Neuropeptide FF receptor 1 (NPFFR1) and NPFFR2 regulate several biological functions and there is a lack of blockers for these receptors that allow the study of their function. Université de Strasbourg researchers have presented details on the design of RF-3286, an NPFFR1 antagonist for the potential treatment of hyperalgesia.
Researchers from GSK plc presented the discovery and preclinical characterization of novel potent and selective inhaled phosphatidylinositol 4-kinase β (PI4Kβ) inhibitor being developed for the treatment of human rhinovirus (HRV)-induced chronic obstructive pulmonary disease (COPD) exacerbations.
Lamkap Bio Alpha AG's κλ bispecific antibodies include a κ light chain recognizing one target and a λ light chain recognizing a second target. The company has presented data showing the benefit of combining a bispecific antibody targeting CEA (CEACAM5) on tumor cells and CD3 on T cells, NILK-2301, and a bispecific antibody targeting CEA on tumor cells and CD28 on T cells, NILK-3301.
Polycomb repressive complex 2 (PRC2) is composed of several subunits, such as EZH2, EED and SUZ12, and is a regulator of cell proliferation and development. Targeting the allosteric subunit EED may be a new approach for fully inhibiting PRC2 complex activity and addressing the limitations of EZH2 inhibition.
Immune checkpoint inhibitors are useful for the treatment of solid tumors, but in many tumors, only partial response is achieved. The antitumoral efficacy of Enlivex Therapeutics Ltd.'s Allocetra-OTS, a cellular therapy, was investigated in animal models of solid tumors.
RSS
